青光眼遗传风险预测的未来:叙述性综述
综述总结了已知POAG遗传学、内表型(如眼压或杯盘比)对预测的帮助,以及多基因风险评分(PRS)在风险分层中的应用前景。结论认为青光眼遗传学进展为基于遗传风险预测的风险分层打开了大门,PRS在预测POAG最高风险人群方面显示出良好前景。
要点
- PRS聚合个体多个遗传变异的疾病风险,在预测POAG最高风险人群方面显示出良好前景。
- 内表型如眼压或杯盘比可帮助POAG的遗传风险预测。
- 未来需评估PRS在直接面向消费者基因检测中及跨不同祖先群体的成本效益。
核心结论
- 青光眼遗传学进展为基于遗传风险预测的风险分层打开了大门。
- PRS方法在预测POAG最高风险人群方面显示出良好前景,若能据此改善临床结局则可提高疗效。
研究设计与样本
- 综述围绕一系列问题展开,解释POAG遗传学发现转化中的挑战与机遇。
主要发现
- 全基因组关联研究已定位多个POAG基因。
- 遗传信息可组合为多基因风险评分(PRS),聚合个体多个遗传变异的疾病风险。
- 综述讨论了可用样本量及未来样本量增加对预测方法效用的可能影响。
- 综述探讨了PRS用于风险分层的场景,以及同时携带高外显率突变和不利PRS的POAG高风险个体的应用。
- 综述讨论了应用这些检测的公平性问题及不同祖先群体预测前景。
临床怎么用
- 可考虑将PRS用于POAG风险分层,识别最高风险个体。
- 对携带高外显率突变且PRS不利的个体,可探索个体化风险评估。
- 应用遗传检测时需关注不同祖先群体间的公平性。
局限性
- 本文为非系统性叙述性综述,未按系统检索方法汇总证据。
- 综述指出在直接面向消费者基因检测中及跨不同祖先群体评估青光眼PRS成本效益尚需未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glaucoma is the world's leading cause of irreversible blindness. Primary open-angle glaucoma (POAG) is typically asymptomatic early in the disease process, and unfortunately, many are diagnosed too late to prevent vision loss. OBSERVATIONS: Genome-wide association studies, which evaluate the association between genetic variants and phenotype across the genome, have mapped many genes for POAG. As well as uncovering new biology, genetic information can be combined into a polygenic risk score (PRS), which aggregates an individual's disease risk over many genetic variants. In this nonsystematic review, performed from June 21, 2019, to October 1, 2020, we address a series of questions to explain the challenges and opportunities in translating genetic discoveries in POAG. We summarize what is known about POAG genetics and how its endophenotypes, such as intraocular pressure or cup-disc ratio, can help with prediction. We discuss the sample sizes available and how increases in the future may have an effect on the utility of prediction approaches. We explore particular scenarios, such as the use of PRS in risk stratification, and applications for individuals who are particularly high risk for POAG as a result of them carrying both a high penetrance mutation and an unfavorable PRS. Finally, we discuss the issue of equity in applying these tests and the prospects for prediction for people from various ancestry groups. The cost-effectiveness evaluation of glaucoma PRS in direct-to-consumer genetic testing and across different ancestry groups is warranted in future research. CONCLUSIONS AND RELEVANCE: Advances in glaucoma genetics have opened the door for risk stratification based on genetic risk predictions. The PRS approach has shown good promise in predicting who will be at highest risk of POAG, which could improve outcomes if these predictions can be acted on to result in improved clinical outcomes.
引用
- Han X, Hewitt AW, MacGregor S, et al. Predicting the Future of Genetic Risk Profiling of Glaucoma: A Narrative Review. JAMA Ophthalmol. 2021. PMID: 33331888. doi:10.1001/jamaophthalmol.2020.5404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。